Stay updated with breaking news from Hardi mundl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bayer announced that asundexian, a novel factor XIa inhibitor being evaluated for secondary prevention of stroke, has received fast track designation from the FDA. The drug is being studied for secondary prevention in patients with noncardioembolic ischemic stroke, according to a press release from the company. ....